Abstract:The dengue virus (DENV), which causes dengue, infects 100 to 300 million people globally each year [1]. Aedes aegypti mosquitoes carry the Dengue virus, which causes dengue fever, which is still a serious global health risk, particularly in tropical and subtropical areas. Since there are now no targeted antiviral therapies and due to difficulties with traditional vector control techniques, the focus has shifted to developing vaccines as the main preventive measure. In order to create a variety of vaccination forms, including live attenuated, recombinant subunit, inactivated virus, viral vectored, DNA, and mRNA vaccines, scientists have targeted E protein and NS1. An important advancement in the fight against Dengue fever has been the development of vaccinations that are able to neutralize all four serotypes. But there are obstacles such as lack of vaccine effectiveness against specific serotypes, side effects produced by vaccine in progeny and vaccine-induced immunological enhancement (ADE).Immunization can lessen the burden on healthcare systems, lower the number of hospitalizations caused by dengue, and help stop outbreaks. The development and implementation of dengue vaccine research are significantly accelerated by international cooperation, public-private partnerships, and regulatory cooperation. Effective programs show how crucial it is to work together to combat dengue fever on a worldwide scale. The difficulties involved in developing a dengue vaccine, ongoing funding, campaigning, and research are crucial. There are several viable approaches to increase the efficacy and accessibility of the Dengue vaccine, including cross-disciplinary cooperation, novel vaccination platforms, and emerging technology. In conclusion, overcoming obstacles unique to each serotype, embracing creative approaches to vaccine design, and negotiating scientific intricacies are all necessary steps on the path to developing successful Dengue virus vaccines. The convergence of state-of-the-art technologies, computational modeling, and cooperative research endeavors can potentially realize the objective of vaccination-based comprehensive dengue prevention.

Brazil's record dengue surge: why a vaccine campaign is unlikely to stop it

Dengue fever: Brazil rushes out vaccine as climate change fuels unprecedented surge

Brazil is hoping and waiting for a new vaccine as dengue rages

The greatest Dengue epidemic in Brazil: Surveillance, Prevention, and Control

Dengue outbreaks in Brazil and Latin America: the new and continuing challenges

Low vaccine coverage and varicella outbreaks in Brazil − 2019-2022

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations

[The dengue vaccine: a major scientific challenge and a public health issue]

Changing epidemiology of dengue fever in children in South America

Malaria vaccination: hurdles to reach high-risk children

Vaccines for neglected and emerging diseases in Brazil by 2030: the "valley of death" and opportunities for RD&I in Vaccinology 4.0

[Observations on the dengue vaccination strategy in Argentina]

Systematic review of dengue vaccine efficacy

Overview of childhood vaccination coverage in Brazil and the impact of the COVID-19 pandemic: Is our children's health at risk? A review of pre-COVID-19 periods and during the COVID-19 pandemic

Advancement of Dengue Virus Vaccine: Progress and Challenges

Dengue Fever: Causes, Complications, and Vaccine Strategies

Dengue Vaccine Research Challenges Toward Independency of Vaccine Seed in Indonesia

Access to vaccines in Brazil and the global dynamics of the Health Economic-Industrial Complex

Is new dengue vaccine efficacy data a relief or cause for concern?

The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review

Lessons Learned from the COVID-19 Pandemic: Interpreting Vaccination Strategies in a Nationwide Demographic Study